ClinicalTrials.gg
CompletedNCT01351350Updated Aug 8, 2019Results posted

Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies

A Phase 1 interventional study of MLN0128 and paclitaxel in Advanced Solid Malignancies and Hematologic Malignancies, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-08.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
68
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 821 studies in Hematologic Neoplasms with a site in United States — 181 open to participants now, 276 under way, 12 of them phase 3. Hematologic Neoplasms · United States.

Enrollment
212th of 658
68 · median 40
Started
2011
with 25 others
Phase 1
195 of 821
35 open now
Registered
180th of 821
by date

Among the 821 studies in Hematologic Neoplasms with a site in United States, this one is the 212th largest by enrollment of the 658 interventional ones that give a count, is one of 26 that started in 2011, is one of 195 in phase 1, and was the 180th registered.

Hematologic Neoplasms

1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

181 of the 821 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

176 more — sign in →

All 181 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 314 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 821 studies in Hematologic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a Phase I, open label, dose escalation study of oral administration of MLN0128 in combination with paclitaxel, with/without trastuzumab, in participants with advanced solid malignancies.

Read the detailed description

This is a Phase I, open-label study consisting of a dose escalation phase in advanced solid malignancies to determine the maximum tolerated dose (MTD) of oral administration of MLN0128 in 1 or more dosing schedules, combined with paclitaxel on Days 1, 8 and 15 of each cycle, followed by an expansion phase for further safety and preliminary efficacy.

Once the MTD is determined for each of the dosing schedules evaluated, a dose and schedule will be selected for the expansion phase, which may enroll participants into 2 arms in parallel:

  • Arm A will consist of HER2- unknown cancer participants receiving MLN0128+paclitaxel
  • Arm B will consist of HER2+ cancer participants receiving MLN0128+paclitaxel plus weekly trastuzumab
03

Conditions studied

  • Advanced Solid Malignancies
  • Hematologic Malignancies

Keywords

  • Solid tumor, mTORC1/2 inhibitors, HER2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary written consent
  • Locally advanced or solid tumors with the exception of primary brain tumor, and have failed or are not eligible for standard of care therapy
  • (ECOG) performance status 0-1
  • Ability to swallow oral medications
  • For women of , negative serum or urine pregnancy test within 14 days prior to the first study drug administration and use of physician-approved method of from 30 days prior to 30 days following the last study drug administration
  • Male participants must be surgically sterile or must agree to use physician-approved contraception during the study and for 30 days following the last study drug administration
  • Clinical laboratory values as specified in the protocol
  • For expansion phase (Arm A) - -/unknown participants will be enrolled
  • For expansion phase (Arm B) - HER2+ cancer participants will be enrolled

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of primary brain tumor
  • Have received prior cancer or other therapy within 2 weeks prior to the first administration of study drug
  • Known impaired cardiac function or cardiac disease
  • Known treatment with systemic within one week prior to the first administration of study drug
  • Diabetes mellitus
  • (HIV) infection
  • Known active cardiovascular disease condition as specified in protocol
  • Pregnancy (positive serum or urine pregnancy test) or breast feeding
  • Malabsorption due to prior gastrointestinal (GI) surgery, GI disease
  • Other clinically significant co-morbidities

Please note that there are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.

Site personnel will explain the trial in detail and answer any question you may have if you do qualify for the study. You can then decide whether or not you wish to participate. If you do not qualify for the trial, site personnel will explain the reasons

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    MLN0128P 30 mg QW

    MLN0128 and paclitaxel (MLN0128P): MLN0128 30 mg, capsule, orally, once weekly (QW) + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.

    Drug: MLN0128 · Drug: paclitaxel

  • Experimental
    MLN0128P 40 mg QW

    MLN0128 40 mg, capsule, orally, once a week (QW) + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.

    Drug: MLN0128 · Drug: paclitaxel

  • Experimental
    MLN0128P 6 mg QD×3d QW

    MLN0128 6 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.

    Drug: MLN0128 · Drug: paclitaxel

  • Experimental
    MLN0128P 7 mg QD×3d QW

    MLN0128 7 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.

    Drug: MLN0128 · Drug: paclitaxel

  • Experimental
    MLN0128P 8 mg QD×3d QW

    MLN0128 8 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.

    Drug: MLN0128 · Drug: paclitaxel

  • Experimental
    MLN0128P 9 mg QD×3d QW

    MLN0128 9 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.

    Drug: MLN0128 · Drug: paclitaxel

  • Experimental
    MLN0128P 10 mg QD×3d QW

    MLN0128 10 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.

    Drug: MLN0128 · Drug: paclitaxel

  • Experimental
    MLN0128P 7 mg QD×5d QW

    MLN0128 7 mg, capsule, orally, once daily 5 days on/2 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in the Dose Escalation Phase.

    Drug: MLN0128 · Drug: paclitaxel

  • Experimental
    MLN0128P 8 mg QD×3d QW HER2-

    MLN0128 8 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 of a 4-week cycle in human epidermal growth factor receptor 2 negative (HER-) cancer participants until disease progression or unacceptable toxicity for up to 1 year in the Expansion Phase.

    Drug: MLN0128 · Drug: paclitaxel

  • Experimental
    MLN0128PH 8 mg QD×3d QW HER2+

    MLN0128 + paclitaxel + trastuzumab (MLN0128PH): MLN0128 8 mg, capsule, orally, once daily 3 days on/4 days off each week + paclitaxel 80 mg/m\^2, 1 hour infusion, on Days 1, 8 and 15 plus trastuzumab 4 mg/kg loading dose on Day 1 followed by 2 mg/kg, intravenous each week of a 4-week cycle in HER+ cancer participants until disease progression or unacceptable toxicity for up to 1 year in the Expansion Phase.

    Drug: MLN0128 · Drug: paclitaxel · Drug: trastuzumab

Interventions

06

What researchers measure

Primary outcomes

  1. Dose Escalation Phase: Maximum Tolerated Dose (MTD)

    MTD is the highest dose level at which the participants tolerate treatment without dose-limiting toxicities during the first cycle (28 days) of therapy.

    Time frame: Cycle 1: Days 1 to 28

  2. Dose Escalation Phase: Number of Participants With at Least 1 Dose Limiting Toxicity (DLT)

    DLT was defined as any of the following occurring during Cycle 1 (Days 1-28) and attributable to MLN0128P: Grade ≥ 3 nonhematologic toxicity; Grade 3 thrombocytopenia with hemorrhage; Grade 4 neutropenia lasting \> 7 days in the absence of growth factor support; Grade 4 neutropenia of any duration associated with fever 38.5 degrees C and/or infection; Any other Grade 4 hematologic toxicity; Inability to administer at least 75 % of doses of MLN0128 within Cycle 1 due to drug-related toxicity; Any clinically significant occurrence which the investigators and sponsor agree would place participants at undue safety risk; Participants who experienced an adverse event (AE) that met the definition for a DLT.

    Time frame: Cycle 1: Days 1 to 28

  3. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants with Complete Response (CR) and Partial Response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Each cycle was a 28 day cycle. CR was defined as the disappearance of all target lesions and for non-target lesions, the disappearance of all non-target lesions and normalization of tumor marker level. PR was defined of at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD and for non-target lesions.

    Time frame: At screening and thereafter every 2 cycles of treatment until disease progression (Up to 65.8 weeks)

  4. Percentage of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events(SAEs), AEs Resulting in Discontinuation of MLN0128 and Fatal AEs Within 30 Days of Last Dose of Study Drug

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

    Time frame: First dose of study drug through 30 days after the administration of the last dose of study drug (Up to approximately 91.4 weeks)

Secondary outcomes

  1. Cmax: Maximum Observed Plasma Concentration for MLN0128

    Participants in the 6 mg QD×3d QW and 9 mg QD×3d QW were dosed with MLN0128 in conjunction with paclitaxel during Cycle 1 and Cycle 2 when PK was collected. Participants in the 7 mg QD×3d QW cohorts were dosed with paclitaxel during Cycle 1, but were subsequently switched to MLN0128 being dosed 24 hours after paclitaxel infusion Cycle 2 (i e, C2D2). In all the other dosing cohorts, MLN0128 was dosed 24 hours after paclitaxel infusion. Cycle 1: Data was collected at Day 1 for the 6, 7 and 9 mg QD×3d QW arms and at Day 2 for the 8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms. Cycle 2: Data was collected at Day 1 for the 6 and 9 mg QD×3d QW arms and at Day 2 for the 7,8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms.

    Time frame: Cycles 1 and 2: Day 1 or 2

  2. Cmin: Minimum Observed Plasma Concentration for MLN0128

    Participants in the 6 mg QD×3d QW and 9 mg QD×3d QW were dosed with MLN0128 in conjunction with paclitaxel during Cycle 1 and Cycle 2 when PK was collected. Participants in the 7 mg QD×3d QW cohorts were dosed with paclitaxel during Cycle 1, but were subsequently switched to MLN0128 being dosed 24 hours after paclitaxel infusion Cycle 2 (i e, C2D2). In all the other dosing cohorts, MLN0128 was dosed 24 hours after paclitaxel infusion. Cycle 1: Data was collected at Day 1 for the 6, 7 and 9 mg QD×3d QW arms and at Day 2 for the 8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms. Cycle 2: Data was collected at Day 1 for the 6 and 9 mg QD×3d QW arms and at Day 2 for the 7,8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms.

    Time frame: Cycles 1 and 2: Day 1 or 2

  3. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for MLN0128

    Participants in the 6 mg QD×3d QW and 9 mg QD×3d QW were dosed with MLN0128 in conjunction with paclitaxel during Cycle 1 and Cycle 2 when PK was collected. Participants in the 7 mg QD×3d QW cohorts were dosed with paclitaxel during Cycle 1, but were subsequently switched to MLN0128 being dosed 24 hours after paclitaxel infusion Cycle 2 (i.e., C2D2). In all the other dosing cohorts, MLN0128 was dosed 24 hours after paclitaxel infusion. Cycle 1: Data was collected at Day 1 for the 6, 7 and 9 mg QD×3d QW arms and at Day 2 for the 8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms. Cycle 2: Data was collected at Day 1 for the 6 and 9 mg QD×3d QW arms and at Day 2 for the 7,8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms.

    Time frame: Cycles 1 and 2: Day 1 or 2

  4. Terminal Phase Elimination Half-life (T1/2) for MLN0128

    Time frame: Cycle 1 Day 1

  5. AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for MLN0128

    Time frame: Cycle 1 Day 1

  6. AUC(0-6): Area Under the Plasma Concentration-time Curve From Time 0 to 6 Hours for MLN0128

    Participants in the 6 mg QD×3d QW and 9 mg QD×3d QW were dosed with MLN0128 in conjunction with paclitaxel during Cycle 1 and Cycle 2 when PK was collected. Participants in the 7 mg QD×3d QW cohorts were dosed with paclitaxel during Cycle 1, but were subsequently switched to MLN0128 being dosed 24 hours after paclitaxel infusion Cycle 2 (i e, C2D2). In all the other dosing cohorts, MLN0128 was dosed 24 hours after paclitaxel infusion. Cycle 1: Data was collected at Day 1 for the 6, 7 and 9 mg QD×3d QW arms and at Day 2 for the 8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms. Cycle 2: Data was collected at Day 1 for the 6 and 9 mg QD×3d QW arms and at Day 2 for the 7,8 and 10 mg QD×3d QW, 30 and 40 mg QW arms.

    Time frame: Cycles 1 and 2: Day 1 or 2

  7. Cmax: Maximum Observed Plasma Concentration for Paclitaxel

    Time frame: Cycles 1 and 2: Day 1

  8. Cmin: Minimum Observed Plasma Concentration for Paclitaxel

    Participants in the 6 mg QD×3d QW and 9 mg QD×3d QW were dosed with MLN0128 in conjunction with paclitaxel during Cycle 1 and Cycle 2 when PK was collected. Participants in the 7 mg QD×3d QW cohorts were dosed with paclitaxel during Cycle 1, but were subsequently switched to MLN0128 being dosed 24 hours after paclitaxel infusion Cycle 2 (i e, C2D2). In all the other dosing cohorts, MLN0128 was dosed 24 hours after paclitaxel infusion. Cycle 1: Data was collected at Day 1 for the 6, 7 and 9 mg QD×3d QW arms and at Day 2 for the 8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms. Cycle 2: Data was collected at Day 1 for the 6 and 9 mg QD×3d QW arms and at Day 2 for the 7,8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms.

    Time frame: Cycles 1 and 2: Day 1 or 2

  9. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Paclitaxel

    Time frame: Cycles 1 and 2: Day 1

  10. Terminal Phase Elimination Half-life (T1/2) for Paclitaxel

    Time frame: Cycle 1 Day 1

  11. AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Paclitaxel

    Time frame: Cycle 1 Day 1

  12. AUC(0-6): Area Under the Plasma Concentration-time Curve From Time 0 to 6 Hours for Paclitaxel

    Time frame: Cycle 1 Day 1

  13. AUC(0-24): Area Under the Plasma Concentration-time Curve Extrapolated to 24 Hours for Paclitaxel

    Time frame: Cycle 1 Day 1

  14. CL: Total Clearance Calculated Using the Observed Value of the Last Quantifiable Concentration for Paclitaxel

    Time frame: Cycle 1 Day 1

  15. Vss: Volume of Distribution at Steady State Calculated Using the Observed Value of the Last Quantifiable Concentration for Paclitaxel

    Time frame: Cycle 1 Day 1

07

Results

Posted Aug 8, 2019

Participant flow

Participants took part in the study at three investigative sites in the United States from 28 February 2011 to 15 Sep 2017.

Participant flow — Overall Study
MilestoneMLN0128P 30 or 40 mg QWMLN0128P 6, 7, 8, 9 or 10 mg QD×3d QWMLN0128P 7 mg QD×5d QWExpansion Cohort MLN0128P 8 mg QD×3d QW HER2-Expansion Cohort MLN0128PH 8mg QD×3d QW HER2+ Plus Trastuzumab
Started82911137
Treated82910137
Dose-escalation evaluable7231000
Completed00000
Not completed82911137
Withdrew: Disease progression513685
Withdrew: Adverse event110120
Withdrew: Participant decision26332
Withdrew: Enrolled but not treated00100

Outcome measures

PrimaryDose Escalation Phase: Maximum Tolerated Dose (MTD)

MTD is the highest dose level at which the participants tolerate treatment without dose-limiting toxicities during the first cycle (28 days) of therapy.

Time frame:
Cycle 1: Days 1 to 28
Reported as:
Number · mg (QD×3d QW)
Dose Escalation Phase: Maximum Tolerated Dose (MTD)
mg (QD×3d QW)Dose Escalation
Dose Escalation Phase: Maximum Tolerated Dose (MTD)8
PrimaryDose Escalation Phase: Number of Participants With at Least 1 Dose Limiting Toxicity (DLT)

DLT was defined as any of the following occurring during Cycle 1 (Days 1-28) and attributable to MLN0128P: Grade ≥ 3 nonhematologic toxicity; Grade 3 thrombocytopenia with hemorrhage; Grade 4 neutropenia lasting \> 7 days in the absence of growth factor support; Grade 4 neutropenia of any duration associated with fever 38.5 degrees C and/or infection; Any other Grade 4 hematologic toxicity; Inability to administer at least 75 % of doses of MLN0128 within Cycle 1 due to drug-related toxicity; Any clinically significant occurrence which the investigators and sponsor agree would place participants at undue safety risk; Participants who experienced an adverse event (AE) that met the definition for a DLT.

Time frame:
Cycle 1: Days 1 to 28
Reported as:
Number · participants
Dose Escalation Phase: Number of Participants With at Least 1 Dose Limiting Toxicity (DLT)
participantsMLN0128P 30 mg QWMLN0128P 40 mg QWMLN0128P 6 mg QD×3d QWMLN0128P 7 mg QD×3d QWMLN0128P 8 mg QD×3d QWMLN0128P 9 mg QD×3d QWMLN0128P 10 mg QD×3d QWMLN0128P 7 mg QD×5d QW
Dose Escalation Phase: Number of Participants With at Least 1 Dose Limiting Toxicity (DLT)02000222
PrimaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants with Complete Response (CR) and Partial Response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1). Each cycle was a 28 day cycle. CR was defined as the disappearance of all target lesions and for non-target lesions, the disappearance of all non-target lesions and normalization of tumor marker level. PR was defined of at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD and for non-target lesions.

Time frame:
At screening and thereafter every 2 cycles of treatment until disease progression (Up to 65.8 weeks)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsMLN0128P 30 or 40 mg QWMLN0128P 6, 7, 8, 9 or 10 mg QD×3d QWMLN0128P 7 mg QD×5d QWExpansion Cohort MLN0128P 8 mg QD×3d QW HER2-Expansion Cohort MLN0128PH 8mg QDx3d QW HER2+ Plus Trastuzumab
Objective Response Rate (ORR)09441020
SecondaryCmax: Maximum Observed Plasma Concentration for MLN0128

Participants in the 6 mg QD×3d QW and 9 mg QD×3d QW were dosed with MLN0128 in conjunction with paclitaxel during Cycle 1 and Cycle 2 when PK was collected. Participants in the 7 mg QD×3d QW cohorts were dosed with paclitaxel during Cycle 1, but were subsequently switched to MLN0128 being dosed 24 hours after paclitaxel infusion Cycle 2 (i e, C2D2). In all the other dosing cohorts, MLN0128 was dosed 24 hours after paclitaxel infusion. Cycle 1: Data was collected at Day 1 for the 6, 7 and 9 mg QD×3d QW arms and at Day 2 for the 8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms. Cycle 2: Data was collected at Day 1 for the 6 and 9 mg QD×3d QW arms and at Day 2 for the 7,8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms.

Time frame:
Cycles 1 and 2: Day 1 or 2
Reported as:
Mean · ng/mL
Cmax: Maximum Observed Plasma Concentration for MLN0128
ng/mLMLN0128P 30 mg QWMLN0128P 40 mg QWMLN0128P 6 mg QD×3d QWMLN0128P 7 mg QD×3d QWMLN0128P 8 mg QD×3d QWMLN0128P 9 mg QD×3d QWMLN0128P 10 mg QD×3d QWMLN0128P 7 mg QD×5d QW
Cycle 1245.0 (136.00 to 456.00)345.5 (306.00 to 385.00)26.7 (19.10 to 40.30)31.1 (20.40 to 52.40)41.8 (19.80 to 79.70)34.2 (23.90 to 47.10)100.0 (57.50 to 162.00)53.5 (26.70 to 101.00)
Cycle 2242.2 (105.00 to 356.00)107.0 (107.00 to 107.00)33.8 (14.70 to 58.70)45.5 (40.40 to 50.50)53.1 (46.00 to 57.20)23.0 (10.80 to 36.60)80.1 (21.00 to 166.00)45.3 (11.60 to 79.50)
SecondaryCmin: Minimum Observed Plasma Concentration for MLN0128

Participants in the 6 mg QD×3d QW and 9 mg QD×3d QW were dosed with MLN0128 in conjunction with paclitaxel during Cycle 1 and Cycle 2 when PK was collected. Participants in the 7 mg QD×3d QW cohorts were dosed with paclitaxel during Cycle 1, but were subsequently switched to MLN0128 being dosed 24 hours after paclitaxel infusion Cycle 2 (i e, C2D2). In all the other dosing cohorts, MLN0128 was dosed 24 hours after paclitaxel infusion. Cycle 1: Data was collected at Day 1 for the 6, 7 and 9 mg QD×3d QW arms and at Day 2 for the 8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms. Cycle 2: Data was collected at Day 1 for the 6 and 9 mg QD×3d QW arms and at Day 2 for the 7,8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms.

Time frame:
Cycles 1 and 2: Day 1 or 2

No measurements were reported for this outcome.

SecondaryTmax: Time to Reach the Maximum Plasma Concentration (Cmax) for MLN0128

Participants in the 6 mg QD×3d QW and 9 mg QD×3d QW were dosed with MLN0128 in conjunction with paclitaxel during Cycle 1 and Cycle 2 when PK was collected. Participants in the 7 mg QD×3d QW cohorts were dosed with paclitaxel during Cycle 1, but were subsequently switched to MLN0128 being dosed 24 hours after paclitaxel infusion Cycle 2 (i.e., C2D2). In all the other dosing cohorts, MLN0128 was dosed 24 hours after paclitaxel infusion. Cycle 1: Data was collected at Day 1 for the 6, 7 and 9 mg QD×3d QW arms and at Day 2 for the 8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms. Cycle 2: Data was collected at Day 1 for the 6 and 9 mg QD×3d QW arms and at Day 2 for the 7,8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms.

Time frame:
Cycles 1 and 2: Day 1 or 2
Reported as:
Median · hours
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for MLN0128
hoursMLN0128P 30 mg QWMLN0128P 40 mg QWMLN0128P 6 mg QD×3d QWMLN0128P 7 mg QD×3d QWMLN0128P 8 mg QD×3d QWMLN0128P 9 mg QD×3d QWMLN0128P 10 mg QD×3d QWMLN0128P 7 mg QD×5d QW
Cycle 13.0 (0.50 to 5.92)3.0 (2.00 to 4.00)2.0 (2.00 to 3.83)3.0 (1.03 to 4.08)5.6 (1.02 to 5.65)4.1 (3.67 to 6.00)1.0 (0.53 to 2.17)1.6 (0.65 to 5.53)
Cycle 22.0 (1.87 to 3.90)4.0 (4.00 to 4.00)4.0 (2.00 to 4.02)2.0 (1.97 to 2.00)1.0 (0.92 to 4.00)5.5 (2.00 to 6.00)2.0 (1.00 to 5.75)2.7 (0.50 to 5.72)
SecondaryTerminal Phase Elimination Half-life (T1/2) for MLN0128
Time frame:
Cycle 1 Day 1
Reported as:
Mean · hours
Terminal Phase Elimination Half-life (T1/2) for MLN0128
hoursMLN0128P 6 mg QD×3d QWMLN0128P 7 mg QD×3d QW
Terminal Phase Elimination Half-life (T1/2) for MLN01286.6 (6.36 to 6.91)7.2 (7.03 to 7.30)
SecondaryAUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for MLN0128
Time frame:
Cycle 1 Day 1
Reported as:
Mean · ng*hr/mL
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for MLN0128
ng*hr/mLMLN0128P 6 mg QD×3d QWMLN0128P 7 mg QD×3d QW
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for MLN0128206.5 (183.00 to 230.00)286.0 (269.00 to 303.00)
SecondaryAUC(0-6): Area Under the Plasma Concentration-time Curve From Time 0 to 6 Hours for MLN0128

Participants in the 6 mg QD×3d QW and 9 mg QD×3d QW were dosed with MLN0128 in conjunction with paclitaxel during Cycle 1 and Cycle 2 when PK was collected. Participants in the 7 mg QD×3d QW cohorts were dosed with paclitaxel during Cycle 1, but were subsequently switched to MLN0128 being dosed 24 hours after paclitaxel infusion Cycle 2 (i e, C2D2). In all the other dosing cohorts, MLN0128 was dosed 24 hours after paclitaxel infusion. Cycle 1: Data was collected at Day 1 for the 6, 7 and 9 mg QD×3d QW arms and at Day 2 for the 8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms. Cycle 2: Data was collected at Day 1 for the 6 and 9 mg QD×3d QW arms and at Day 2 for the 7,8 and 10 mg QD×3d QW, 30 and 40 mg QW arms.

Time frame:
Cycles 1 and 2: Day 1 or 2
Reported as:
Mean · ng*hr/mL
AUC(0-6): Area Under the Plasma Concentration-time Curve From Time 0 to 6 Hours for MLN0128
ng*hr/mLMLN0128P 30 mg QWMLN0128P 40 mg QWMLN0128P 6 mg QD×3d QWMLN0128P 7 mg QD×3d QWMLN0128P 8 mg QD×3d QWMLN0128P 9 mg QD×3d QWMLN0128P 10 mg QD×3d QW
Cycle 1753.7 (428.00 to 1290.00)1325.0 (1210.00 to 1440.00)104.4 (73.70 to 146.00)121.7 (82.70 to 187.00)139.9 (58.00 to 282.00)146.2 (99.20 to 229.00)347.0 (203.00 to 505.00)
Cycle 2883.6 (464.00 to 1340.00)505.0 (505.00 to 505.00)106.8 (55.50 to 165.00)174.0 (162.00 to 186.00)210.3 (143.00 to 253.00)72.6 (28.10 to 144.00)283.9 (65.60 to 660.00)
SecondaryCmax: Maximum Observed Plasma Concentration for Paclitaxel
Time frame:
Cycles 1 and 2: Day 1
Reported as:
Mean · ng/mL
Cmax: Maximum Observed Plasma Concentration for Paclitaxel
ng/mLMLN0128P 30 mg QWMLN0128P 40 mg QWMLN0128P 6 mg QD×3d QWMLN0128P 7 mg QD×3d QWMLN0128P 8 mg QD×3d QWMLN0128P 9 mg QD×3d QWMLN0128P 10 mg QD×3d QWMLN0128P 7 mg QD×5d QW
Cycle 1, Day 12538.0 (1090.00 to 3220.00)2355.0 (2210.00 to 2500.00)1933.3 (1280.00 to 3170.00)1942.5 (1540.00 to 2420.00)1620.0 (1290.00 to 1990.00)3798.3 (1270.00 to 11100.00)2906.9 (2090.00 to 4020.00)1637.7 (410.00 to 2770.00)
Cycle 2, Day 13462.5 (2300.00 to 4210.00)1500.0 (1500.00 to 1500.00)1200.3 (421.00 to 2090.00)1550.0 (1550.00 to 1550.00)3103.3 (1440.00 to 4890.00)1602.3 (597.00 to 2350.00)2964.0 (1560.00 to 4070.00)1765.7 (654.00 to 2670.00)
SecondaryCmin: Minimum Observed Plasma Concentration for Paclitaxel

Participants in the 6 mg QD×3d QW and 9 mg QD×3d QW were dosed with MLN0128 in conjunction with paclitaxel during Cycle 1 and Cycle 2 when PK was collected. Participants in the 7 mg QD×3d QW cohorts were dosed with paclitaxel during Cycle 1, but were subsequently switched to MLN0128 being dosed 24 hours after paclitaxel infusion Cycle 2 (i e, C2D2). In all the other dosing cohorts, MLN0128 was dosed 24 hours after paclitaxel infusion. Cycle 1: Data was collected at Day 1 for the 6, 7 and 9 mg QD×3d QW arms and at Day 2 for the 8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms. Cycle 2: Data was collected at Day 1 for the 6 and 9 mg QD×3d QW arms and at Day 2 for the 7,8 and 10 mg QD×3d QW, 7 mg QD×5d QW, 30 and 40 mg QW arms.

Time frame:
Cycles 1 and 2: Day 1 or 2

No measurements were reported for this outcome.

SecondaryTmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Paclitaxel
Time frame:
Cycles 1 and 2: Day 1
Reported as:
Median · hours
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Paclitaxel
hoursMLN0128P 30 mg QWMLN0128P 40 mg QWMLN0128P 6 mg QD×3d QWMLN0128P 7 mg QD×3d QWMLN0128P 8 mg QD×3d QWMLN0128P 9 mg QD×3d QWMLN0128P 10 mg QD×3d QWMLN0128P 7 mg QD×5d QW
Cycle 1, Day 11.1 (1.02 to 1.17)1.1 (1.03 to 1.17)1.1 (1.00 to 1.15)1.2 (0.87 to 1.55)1.2 (1.08 to 1.62)1.1 (1.00 to 2.22)1.1 (0.52 to 1.87)1.5 (1.00 to 1.88)
Cycle 2, Day 11.1 (1.00 to 1.47)1.2 (1.2 to 1.2)1.6 (1.0 to 1.6)1.4 (1.20 to 1.50)1.2 (1.07 to 1.75)1.2 (1.08 to 1.83)1.0 (0.95 to 1.17)1.1 (1.02 to 1.55)
SecondaryTerminal Phase Elimination Half-life (T1/2) for Paclitaxel
Time frame:
Cycle 1 Day 1
Reported as:
Mean · hours
Terminal Phase Elimination Half-life (T1/2) for Paclitaxel
hoursMLN0128P 6 mg QD×3d QWMLN0128P 7 mg QD×3d QWMLN0128P 9 mg QD×3d QWMLN0128P 10 mg QD×3d QW
Terminal Phase Elimination Half-life (T1/2) for Paclitaxel10.0 (9.93 to 10.00)9.1 (8.83 to 9.48)9.6 (8.19 to 11.60)9.3 (9.10 to 9.53)
SecondaryAUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Paclitaxel
Time frame:
Cycle 1 Day 1
Reported as:
Mean · ng*hr/mL
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Paclitaxel
ng*hr/mLMLN0128P 6 mg QD×3d QWMLN0128P 7 mg QD×3d QWMLN0128P 9 mg QD×3d QWMLN0128P 10 mg QD×3d QW
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Paclitaxel4590.0 (3440.00 to 5740.00)4790.0 (4040.00 to 6270.00)5002.0 (2910.00 to 6330.00)5485.0 (4550.00 to 6420.00)
SecondaryAUC(0-6): Area Under the Plasma Concentration-time Curve From Time 0 to 6 Hours for Paclitaxel
Time frame:
Cycle 1 Day 1
Reported as:
Mean · ng*hr/mL
AUC(0-6): Area Under the Plasma Concentration-time Curve From Time 0 to 6 Hours for Paclitaxel
ng*hr/mLMLN0128P 30 mg QWMLN0128P 40 mg QWMLN0128P 6 mg QD×3d QWMLN0128P 7 mg QD×3d QWMLN0128P 8 mg QD×3d QWMLN0128P 9 mg QD×3d QWMLN0128P 10 mg QD×3d QWMLN0128P 7 mg QD×5d QW
AUC(0-6): Area Under the Plasma Concentration-time Curve From Time 0 to 6 Hours for Paclitaxel3198.3 (1560.00 to 4140.00)3515.0 (2930.00 to 4100.00)2620.0 (1800.00 to 3970.00)3157.5 (2810.00 to 3550.00)2683.3 (1820.00 to 3630.00)5315.0 (1880.00 to 15100.00)3683.8 (2600.00 to 5330.00)2657.0 (1140.00 to 5350.00)
SecondaryAUC(0-24): Area Under the Plasma Concentration-time Curve Extrapolated to 24 Hours for Paclitaxel
Time frame:
Cycle 1 Day 1
Reported as:
Mean · ng*hr/mL
AUC(0-24): Area Under the Plasma Concentration-time Curve Extrapolated to 24 Hours for Paclitaxel
ng*hr/mLMLN0128P 6 mg QD×3d QWMLN0128P 7 mg QD×3d QWMLN0128P 9 mg QD×3d QWMLN0128P 10 mg QD×3d QW
AUC(0-24): Area Under the Plasma Concentration-time Curve Extrapolated to 24 Hours for Paclitaxel3583.3 (2510.00 to 5160.00)4332.5 (3670.00 to 5510.00)6415.0 (2550.00 to 15900.00)5135.0 (4290.00 to 5980.00)
SecondaryCL: Total Clearance Calculated Using the Observed Value of the Last Quantifiable Concentration for Paclitaxel
Time frame:
Cycle 1 Day 1
Reported as:
Mean · L/hr
CL: Total Clearance Calculated Using the Observed Value of the Last Quantifiable Concentration for Paclitaxel
L/hrMLN0128P 6 mg QD×3d QWMLN0128P 7 mg QD×3d QWMLN0128P 9 mg QD×3d QWMLN0128P 10 mg QD×3d QW
CL: Total Clearance Calculated Using the Observed Value of the Last Quantifiable Concentration for Paclitaxel36.2 (24.70 to 47.70)34.8 (22.30 to 45.30)31.2 (22.30 to 48.20)25.8 (19.30 to 32.30)
SecondaryVss: Volume of Distribution at Steady State Calculated Using the Observed Value of the Last Quantifiable Concentration for Paclitaxel
Time frame:
Cycle 1 Day 1
Reported as:
Mean · L
Vss: Volume of Distribution at Steady State Calculated Using the Observed Value of the Last Quantifiable Concentration for Paclitaxel
LMLN0128P 6 mg QD×3d QWMLN0128P 7 mg QD×3d QWMLN0128P 9 mg QD×3d QWMLN0128P 10 mg QD×3d QW
Vss: Volume of Distribution at Steady State Calculated Using the Observed Value of the Last Quantifiable Concentration for Paclitaxel313.5 (189.00 to 438.00)262.0 (219.00 to 306.00)252.2 (149.00 to 441.00)150.0 (120.00 to 180.00)
PrimaryPercentage of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events(SAEs), AEs Resulting in Discontinuation of MLN0128 and Fatal AEs Within 30 Days of Last Dose of Study Drug

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event is any experience that suggests a significant hazard, contraindication, side effect or precaution that: results in death, is life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant.

Time frame:
First dose of study drug through 30 days after the administration of the last dose of study drug (Up to approximately 91.4 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events(SAEs), AEs Resulting in Discontinuation of MLN0128 and Fatal AEs Within 30 Days of Last Dose of Study Drug
percentage of participantsMLN0128P 30 or 40 mg QWMLN0128P 6, 7, 8, 9 or 10 mg QD×3d QWMLN0128P 7 mg QD×5d QWExpansion Cohort MLN0128P 8 mg QD×3d QW HER2-Expansion Cohort MLN0128PH 8mg QDx3d QW HER2+ Plus Trastuzumab
TEAE100100100100100
SAE6341603143
Fatal AEs within 30 Days of Last Dose Study Drug257201514
AEs Resulting in Discontinuation of MLN0128133410150

Adverse events

Collected over First dose of study drug through 30 days after the administration of the last dose of study drug (Up to approximately 91.4 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MLN0128P 30 or 40 mg QW2/8 (25%)5/8 (62.5%)8/8 (100%)
MLN0128P 6, 7, 8, 9 or 10 mg QD×3d QW2/29 (6.9%)12/29 (41.4%)29/29 (100%)
MLN0128P 7 mg QD×5d QW2/10 (20%)6/10 (60%)10/10 (100%)
Expansion Cohort MLN0128P 8 mg QD×3d QW HER2-2/13 (15.4%)4/13 (30.8%)13/13 (100%)
Expansion Cohort MLN0128PH 8mg QD×3d QW HER2+ Plus Trastuzumab1/7 (14.3%)3/7 (42.9%)7/7 (100%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventMLN0128P 30 or 40 mg QWMLN0128P 6, 7, 8, 9 or 10 mg QD×3d QWMLN0128P 7 mg QD×5d QWExpansion Cohort MLN0128P 8 mg QD×3d QW HER2-Expansion Cohort MLN0128PH 8mg QD×3d QW HER2+ Plus Trastuzumab
PneumoniaInfections and infestations1/82/292/102/130/7
Small intestinal obstructionGastrointestinal disorders0/82/290/100/131/7
HaematemesisGastrointestinal disorders0/80/290/100/131/7
GastroenteritisInfections and infestations0/80/290/100/131/7
Endometrial cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/80/290/100/131/7
Oesophageal ulcerGastrointestinal disorders1/80/290/100/130/7
VomitingGastrointestinal disorders1/80/290/101/130/7
SepsisInfections and infestations1/81/290/100/130/7
Laryngeal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/80/290/100/130/7
Oesophageal carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/81/290/100/130/7
Most frequent other events
Showing 10 of 227
Most frequent other events
EventMLN0128P 30 or 40 mg QWMLN0128P 6, 7, 8, 9 or 10 mg QD×3d QWMLN0128P 7 mg QD×5d QWExpansion Cohort MLN0128P 8 mg QD×3d QW HER2-Expansion Cohort MLN0128PH 8mg QD×3d QW HER2+ Plus Trastuzumab
NauseaGastrointestinal disorders4/818/296/106/136/7
VomitingGastrointestinal disorders5/810/293/107/136/7
FatigueGeneral disorders4/819/298/109/134/7
Decreased appetiteMetabolism and nutrition disorders2/812/297/104/134/7
HyperglycaemiaMetabolism and nutrition disorders5/814/293/103/134/7
DiarrhoeaGastrointestinal disorders3/815/296/107/134/7
AnaemiaBlood and lymphatic system disorders4/812/293/104/132/7
DehydrationMetabolism and nutrition disorders4/812/292/103/131/7
StomatitisGastrointestinal disorders2/813/294/105/133/7
ConstipationGastrointestinal disorders3/84/292/101/133/7

Baseline characteristics

All Subjects as Treated (ASaT) population, which consisted of all enrolled participants who received at least 1 dose of MLN0128.

Age, Continuous
Age, Continuous(years)MLN0128P 30 or 40 mg QWMLN0128P 6, 7, 8, 9 or 10 mg QD×3d QWMLN0128P 7 mg QD×5d QWExpansion Cohort MLN0128P 8 mg QD×3d QW HER2-Expansion Cohort MLN0128PH 8mg QDx3d QW HER2+ Plus TrastuzumabTotal
Mean57.3 ± 14.3462.9 ± 9.5758.1 ± 14.7054.2 ± 14.4658.1 ± 8.0359.3 ± 12.07
Sex: Female, Male
Sex: Female, Male(Participants)MLN0128P 30 or 40 mg QWMLN0128P 6, 7, 8, 9 or 10 mg QD×3d QWMLN0128P 7 mg QD×5d QWExpansion Cohort MLN0128P 8 mg QD×3d QW HER2-Expansion Cohort MLN0128PH 8mg QDx3d QW HER2+ Plus TrastuzumabTotal
Female51476638
Male31537129
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MLN0128P 30 or 40 mg QWMLN0128P 6, 7, 8, 9 or 10 mg QD×3d QWMLN0128P 7 mg QD×5d QWExpansion Cohort MLN0128P 8 mg QD×3d QW HER2-Expansion Cohort MLN0128PH 8mg QDx3d QW HER2+ Plus TrastuzumabTotal
Hispanic or Latino010113
Not Hispanic or Latino8281012664
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MLN0128P 30 or 40 mg QWMLN0128P 6, 7, 8, 9 or 10 mg QD×3d QWMLN0128P 7 mg QD×5d QWExpansion Cohort MLN0128P 8 mg QD×3d QW HER2-Expansion Cohort MLN0128PH 8mg QDx3d QW HER2+ Plus TrastuzumabTotal
American Indian or Alaska Native010001
Asian000101
Black or African American010203
White8271010762
Region of Enrollment
Region of Enrollment(Participants)MLN0128P 30 or 40 mg QWMLN0128P 6, 7, 8, 9 or 10 mg QD×3d QWMLN0128P 7 mg QD×5d QWExpansion Cohort MLN0128P 8 mg QD×3d QW HER2-Expansion Cohort MLN0128PH 8mg QDx3d QW HER2+ Plus TrastuzumabTotal
United States8291013767
08

Study locations

3 sites
  • Fort Myers, Florida 33905, United States
  • Oklahoma City, Oklahoma 73104, United States
  • Nashville, Tennessee 37203, United States
09

References and documents

Publications

  • Burris HA 3rd, Kurkjian CD, Hart L, Pant S, Murphy PB, Jones SF, Neuwirth R, Patel CG, Zohren F, Infante JR. TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies. Cancer Chemother Pharmacol. 2017 Aug;80(2):261-273. doi: 10.1007/s00280-017-3343-4. Epub 2017 Jun 10. PubMed 28601972 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2011 to primary completion in Sep 2017, 78 months.

Results were first posted in Aug 2019, 1 year 10 months after primary completion.

Of 95 industry-sponsored phase 1 interventional studies under Hematologic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 78. This study's 78 months is above that.

Counting every sponsor, half of 159 studies reached it within 51 months; a quarter within 28 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2011
First posted
May 10, 2011
StartActual
Feb 28, 2011
Primary completionActual
Sep 15, 2017
CompletionActual
Sep 15, 2017
Results first posted
Aug 8, 2019
Last update
Aug 8, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01351350
Responsible party
Sponsor
First posted
May 10, 2011
Start date
Feb 28, 2011
Primary completion
Sep 15, 2017
Completion
Sep 15, 2017
Results posted
Aug 8, 2019
Last update
Aug 8, 2019

Study contacts

Medical Director
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sapanisertib · Paclitaxel

Start the discussion